Efficacy predictors of immune checkpoint inhibitors in the treatment of metastatic gastric cancer
10.3760/cma.j.cn371439-20210104-00095
- VernacularTitle:免疫检查点抑制剂治疗转移性胃癌疗效预测因子
- Author:
Guangyue HU
1
;
Hong YIN
;
Hui ZHANG
;
Hong LUO
Author Information
1. 苏州大学附属第一医院肿瘤科 215000
- Keywords:
Gastric neoplasms;
Immunotherapy;
Biomarkers
- From:
Journal of International Oncology
2021;48(8):498-501
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immunotherapy has been used more frequently for metastatic gastric cancer that has progressed after chemotherapy, the most commonly used of which are immune checkpoint inhibitors (ICIs). However, the efficacy of ICIs varies greatly among different patients. Therefore, more and more studies have been carried out on biomarkers that predict the efficacy of ICIs. Microsatellite instability and Epstein-Barr virus subtype are relatively accurate biomarkers indicating the response rate of ICIs treatment. The predictive roles of programmed death ligand-1 and tumor mutation burden are still controversial. Tumor infiltrating lymphocyte, tumor-associated macrophages, fibrinogen-like-protein 1, alternative promoters and other predictors are also being studied.
